Dicerna Pharmaceuticals Stock Price To Book

Dicerna Pharmaceuticals fundamentals help investors to digest information that contributes to Dicerna Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Dicerna Stock. The fundamental analysis module provides a way to measure Dicerna Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Dicerna Pharmaceuticals stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Dicerna Pharmaceuticals Company Price To Book Analysis

Dicerna Pharmaceuticals' Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.

P/B

 = 

MV Per Share

BV Per Share

More About Price To Book | All Equity Analysis

Current Dicerna Pharmaceuticals Price To Book

    
  27.64 X  
Most of Dicerna Pharmaceuticals' fundamental indicators, such as Price To Book, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Dicerna Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
Competition

Based on the latest financial disclosure, Dicerna Pharmaceuticals has a Price To Book of 27.64 times. This is 7.63% higher than that of the Healthcare sector and notably higher than that of the Biotechnology industry. The price to book for all United States stocks is 190.64% lower than that of the firm.

Dicerna Price To Book Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Dicerna Pharmaceuticals' direct or indirect competition against its Price To Book to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Dicerna Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Dicerna Pharmaceuticals by comparing valuation metrics of similar companies.
Dicerna Pharmaceuticals is currently under evaluation in price to book category among its peers.

Dicerna Fundamentals

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.

Other Consideration for investing in Dicerna Stock

If you are still planning to invest in Dicerna Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Dicerna Pharmaceuticals' history and understand the potential risks before investing.
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Global Correlations
Find global opportunities by holding instruments from different markets
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Fundamental Analysis
View fundamental data based on most recent published financial statements
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device